Spanish Oncology has established a new standard treatment for breast cancer at early stages, thanks to the results of a new study.
The results have suggested that docentaxel during quimotherapy reduces the risk of recurrence by 32 per cent in women with high-risk but node-negative, early stage breast cancer when cancer has not spread to lymph nodes.
The aim of the research was to test the efficiency between a drug combination of docetaxel and cyclophosphamide (TAC) in comparision with the traditional treatment of fluorouracil, doxorubicin and cyclophosphamide (FAC).
1060 women participating in the study were randomly assigned to receive TAC or FAC after surgery treated. They received treatment one day every three weeks during six cycles.
Scientifics evaluated those criteria: disease-free survival, global survival, treatment security levels and life quality.
The results after six years have shown that adjuvant therapy based on TAC reduce risk of recurrence by 32 per cent and improve disease-free survival. Almost 90 per cent remained disease-free after this period.
"It is a step towards personalized treatments of this tumour, since the goal is to administrate just those therapies aimed at caused a benefit, avoiding secondary effects," said Miguel Martin of Gregorio Maranon Hospital, Madrid.
The findings were published in the New England Journal of Medicine.